Deucravacitinib Formulations for Healthy Subjects
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the trial is for healthy subjects, it's likely that participants should not be on any regular medications.
What makes the drug Deucravacitinib unique compared to other treatments?
What is the purpose of this trial?
The purpose of this study is to evaluate the bioequivalence between immediate release tablets and minitablets of Deucravacitinib (BMS-986165), and the effect of food and pH on the drug levels of the minitablets in healthy adults.
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for healthy adults who can safely take Deucravacitinib, a medication under study. Participants must meet certain health standards but specific inclusion and exclusion criteria are not listed.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of Deucravacitinib in various formulations to assess bioequivalence and the effect of food and pH
Follow-up
Participants are monitored for safety and effectiveness after treatment, including physical examinations
Treatment Details
Interventions
- Deucravacitinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania